677. Comparison of three antimicrobial coated peripherally inserted central venous catheters (PICCs): What is on the horizon?
Session: Poster Abstract Session: Preventing Catheter Associated Infections
Friday, October 21, 2011
Room: Poster Hall B1
Handouts
  • 677_LauraClaburn_sm.pdf (2.2 MB)
  • Comparison of three antimicrobial coated peripherally inserted central venous catheters (PICCs): What is on the horizon.

    Background:  PICCs have been associated with a greater risk of blood stream infection in hospitalized patients, which are non-tunneled and non-cuffed, and prolonged use may predispose them to microbial colonization and biofilm formation. Impregnated PICCs with antimicrobial agents (aPICCs) might reduce the risk of BSI. We report the in vitro efficacy of 2 FDA approved aPICCS [minocycline/rifampin (M/R) and chlorhexidine (CHX)] and novel a combination of both (CHX-M/R) tested against different pathogens.

    Methods: PICCs of M/R and CHX PICCs were compared to CHX-M/R and uncoated PICCs (as a control) against methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa (PS), Candida albicans (CA), and C. glabrata (CG) by challenge in an established biofilm catheter colonization model.

    Results: All aPICCs significantly decreased the colonization of MRSA (6 log reduction) versus uncoated controls (p = 0.005). Only the CHX-M/R coated PICC showed zero biofilm colonization of MRSA, P. aeruginosa, C. albicans, and C. glabrata (p = 0.003) in comparison with the uncoated control PICCs.  The M/R and CHX PICCS showed one-log reduction against PA, and 2-log reductions against CA, and CG.

    Conclusion: The novel CHX-M/R coated PICC was most effective in completely inhibiting biofilm formation of MRSA, PA, CA and CG in an in vitro biofilm colonization model. Further in vivo and clinical testing is warranted.


    Subject Category: N. Hospital-acquired and surgical infections, infection control, and health outcomes including general public health and health services research

    Ray Hachem, MD, Jamal Mohamed, PhD, Ruth Reitzel, MS, Ying Jiang, MS, Tanya Dvorak, Anne-Marie Chaftari, MD and Issam Raad, MD, Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center, Houston, TX

    Disclosures:

    R. Hachem, None

    J. Mohamed, None

    R. Reitzel, None

    Y. Jiang, None

    T. Dvorak, None

    A. M. Chaftari, None

    I. Raad, Cook: Speaker's Bureau, Grant recipient and Licensing agreement or royalty

    Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.